SCHEMBL29317856

SCHEMBL29317856

COc1cc(Oc2ccnc3ccc(Br)cc23)cc(-n2cccn2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.48
DDR2 Q16832 1/20 0.46
GAK O14976 1/20 0.39
EPHB6 O15197 1/20 0.39
RIPK2 O43353 1/20 0.39
STK16 O75716 1/20 0.39
ABL1 P00519 1/20 0.39
ACVR1 Q04771 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
COQ8A Q8NI60 1/20 0.39
NLK Q9UBE8 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
FGFR2 P21802 2/20 0.38
NPC1 O15118 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049315 0.90 DDR2 (0.56) EGFRDDR2PDGFRBPDGFRAFGFR2
SCHEMBL29317844 0.90 DDR2 (0.56) EGFRDDR2PDGFRBPDGFRAFGFR2
SCHEMBL29318171 0.88 DDR2 (0.47) EGFRDDR2PDGFRBPDGFRAFGFR2
SCHEMBL29186534 0.87 DDR2 (0.46) EGFRDDR2GAKRIPK2COQ8A
SCHEMBL30050689 0.87 DDR2 (0.48) EGFRDDR2RIPK2ABL1PDGFRB
SCHEMBL30050332 0.87 DDR2 (0.46) EGFRDDR2GAKRIPK2COQ8A
SCHEMBL29317851 0.87 DDR2 (0.48) EGFRDDR2RIPK2ABL1PDGFRB
SCHEMBL29317833 0.86 DDR2 (0.44) EGFRDDR2PDGFRBPDGFRAFGFR2
SCHEMBL30049820 0.86 DDR2 (0.44) EGFRDDR2PDGFRBPDGFRAFGFR2
SCHEMBL30050441 0.86 EGFR (0.58) EGFRDDR2GAKEPHB6RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 US disclosed
EP-4330233-A1 PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY Chengdu Anticancer Bioscience, Ltd. (CN) 2024-03-06 EP disclosed
WO-2022228549-A1 PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY Chengdu Anticancer Bioscience, Ltd. (CN) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT EGFR 4704/4885DDR2 4341/4885GAK 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.